Michael Bart Sheffery

Teva Biopharmaceuticals USA, Inc. develops and commercializes biological products. It uses albumin-fusion technology to develop and commercialize certain albumin-fusion proteins for therapeutic use. The company was founded by Craig A. Rosen, Steven C. Mayer, Indra Sanyal and Mark A. Rampy in 2005 and is headquartered in Rockville, MD.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany.

Pieris AG develops and markets Anticalin-brand proteins. The firm specializes in the research and development of its Anticalin technology, with focus on deriving therapeutic proteins from human lipocalins. It focuses on solving pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. It offers a pipeline of Anticalin therapeutics that has active and multi-program research and development collaborations with biopharmaceutical companies. The company was founded by Arne Skerra, Steffen Schlehuber, and Claus Schalper in 2001 and is headquartered in Freising, Germany.

YM Biosciences USA, Inc. develops and commercializes pharmaceutical products. The company was founded on November 23, 2005 and is headquartered in Wayne, PA.